ArticleCureus2026
Recurrent Deep (Aggressive) Angiomyxoma of the Pelvis: Serial MRI Documentation of Sustained Complete Radiologic Response During Eight Years of Gonadotropin-Releasing Hormone (GnRH) Agonist Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep (aggressive) angiomyxoma is a rare mesenchymal tumor that primarily affects premenopausal women and is frequently misdiagnosed because of its deep pelvic location, indolent growth, and nonspecific clinical presentation. It is typically multicompartmental and demonstrates a characteristic laminated ("swirled") appearance on T2-weighted magnetic resonance imaging (MRI), reflecting alternating myxoid and fibrous stromal components. Local recurrence is common after surgical resection, making long-term imaging surveillance essential. Tumor expression of estrogen and progesterone receptors provides a biological rationale for hormonal therapy. We report a case of recurrent pelvic deep (aggressive) angiomyxoma in a 45-year-old woman who achieved complete and sustained radiologic remission documented by serial MRI throughout 8 years of continuous gonadotropin-releasing hormone (GnRH) agonist therapy. This uncommon long-term outcome highlights both the potential for durable disease control with hormonal therapy in deep (aggressive) angiomyxoma and the value of MRI for longitudinal assessment of treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.